surmount-1 trial tirzepatide weight loss nondiabetic For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Tirzepatide as Compared with Semaglutide
Description
exclusively for research purposes and is not approved for human consumption
Sergey Terushkin, MD, FACS, is a board-certified surgeon and weight loss specialist at Florida Surgery & Weight Loss Center in Hollywood, FL
Because Retatrutide is still investigational, long-term safety especially outside controlled trials remains less certain
There are a variety of weight loss treatments available on the market, including supplementary dietary pills and surgical options
Gaps to bridge: misalignment between perception, reality and actions in obesity
J., Cartwright, B
